vatalanib has been researched along with Carcinoma, Hepatocellular in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Chan, P; Fan, ST; Ng, K; Pang, R; Poon, RT; Yau, T | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Fan, ST; Kok, TW; Lau, C; Li, Q; Liu, Y; Poon, RT | 1 |
1 review(s) available for vatalanib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
1 trial(s) available for vatalanib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Phthalazines; Pyridines | 2010 |
3 other study(ies) available for vatalanib and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Fluorouracil; Humans; Immunoenzyme Techniques; Interferon-alpha; Liver Neoplasms; Mice; Phthalazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Female; Flow Cytometry; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2011 |
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Carrier Proteins; Caspase 3; Caspases; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Matrix Proteins; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myosin Heavy Chains; Neovascularization, Pathologic; Nonmuscle Myosin Type IIB; Phthalazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |